Status:

COMPLETED

A Study of KRN23 in X-linked Hypophosphatemia

Lead Sponsor:

Kyowa Kirin Co., Ltd.

Collaborating Sponsors:

Kyowa Hakko Kirin Pharma, Inc.

Conditions:

X-linked Hypophosphatemia

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The primary objective of this study is to assess the safety and tolerability of KRN23 after a single intravenous (IV) and subcutaneous (SC) administration in XLH patients.

Eligibility Criteria

Inclusion

  • 18 years or older
  • Clinical diagnosis of XLH
  • TmP/GFR is less than 2.0 mg/dL
  • GFR is 60 mL/min or above

Exclusion

  • Have any sign of active infectious disease or have had an infection requiring treatment with antibiotics within three weeks prior to screening
  • History of known immunodeficiency
  • Lactating females, female patients who are pregnant or planning to become pregnant during the study
  • Use of a pharmacologic vitamin D metabolite or its analog, phosphate, calcimimetics, and ingestion of aluminum hydroxide antacids within 10 days prior to screening and dosing
  • Use of any supplement contained phosphate, calcium and/or vitamin D within 10 days prior to screening and dosing
  • Receipt of live (attenuated) vaccine within 3-months prior to screening
  • Have any condition which, in the opinion of the Investigator, could present a concern for either patient safety or difficulty with data interpretation

Key Trial Info

Start Date :

December 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2013

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT00830674

Start Date

December 1 2008

End Date

May 1 2013

Last Update

June 17 2024

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Yale University School of Medicine

New Haven, Connecticut, United States, 06510

2

General Clinical Research Center, Indiana University School of Medicine

Indianapolis, Indiana, United States, 46202-5250

3

Duke Clinical Research Unit

Durham, North Carolina, United States, 27710

4

University of Texas Health Science Center at Houston

Houston, Texas, United States, 77030